Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Mar 16 2021;51(2):131-148
How This Blind Spot Leads Directly Into the Next Crisis If we cannot explain how GLP-1 agonists exert their multi-system effects, then we cannot reliably determine who benefits from them, why certain responses emerge, or which biological signatures distinguish durable responders from partial responders, early plateauers, non-responders, or individuals at risk for muscle loss, inflammatory rebound, or neuroprotective divergence
The mechanisms behind these TBI benefits are well-characterized in animal studies
Other GLP-1 receptor agonists, including liraglutide and semaglutide, are now being evaluated clinically across several substance use disorder domains (alcohol, nicotine, cocaine, and opioid use disorder), with multiple trials ongoing (NCT05895643, NCT07227948, NCT06924697 at ClinicalTrials.gov) or recently completed (Klausen et al., 2022
Diabetes Obes Metab (2019) 21:231526
US$ 23.90
US$ 29.47
US$ 20.44
US$ 22.55
US$ 23.52
